Study on PF-08634404 for Advanced Liver Cancer (Hepatocellular Carcinoma)
Sponsor: Pfizer
ClinicalTrials ID:NCT07227012
This clinical trial is exploring a new treatment, PF-08634404, given alone or with another drug, ipilimumab, for adults with advanced liver cancer that cannot be removed by surgery and may have spread to other parts of the body.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to understand how a new medicine, PF-08634404, works when used alone or with ipilimumab in treating advanced liver cancer, known as hepatocellular carcinoma (HCC). This type of cancer has either spread to nearby tissues or other parts of the body and cannot be completely removed by surgery. Participants will receive the treatment through an IV, which means the medicine will be given directly into a vein. All treatments will be conducted at clinical trial sites, where medical staff will closely monitor participants.
Eligibility Criteria
Inclusion Criteria
- Be 18 years or older.
- Have advanced liver cancer (HCC) that has spread locally or to other parts of the body, confirmed by medical tests.
- The cancer cannot be completely removed by surgery or has worsened after surgery or other local treatments.
- Have at least one measurable tumor that has not been treated.
- Have good liver and kidney function.
- Have not received any previous whole-body treatment for liver cancer.
- Be in good general health, with a performance status score of 0 or 1.
- Have a Child-Pugh Class A liver function score.
Exclusion Criteria
- Have moderate or severe fluid buildup in the abdomen (ascites).
- Have a history of brain-related liver disease (hepatic encephalopathy).
- Have active cancer spread to the brain or spinal cord.
- Have a high risk of bleeding or abnormal connections between organs (fistula).
- Have had another cancer within the last 3 years.
- Have had an organ or stem cell transplant.
- Have active autoimmune diseases needing treatment in the past 2 years.
- Have significant heart disease within the last 6 months.
- Have had major surgery or severe injury within 4 weeks before starting the study or plan to have major surgery during the study.
- Have a history of severe bleeding disorders or blood clotting issues.
- Have severe ulcers, unhealed wounds, or recent serious gastrointestinal issues.
- Have active or chronic infections.
- Have a history of immune system deficiencies.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Moffitt Cancer Center at Speros | 34638 | Land O' Lakes | Florida |
| Moffitt Cancer Center at SouthShore | 33570 | Ruskin | Florida |
| Moffitt Cancer Center - International Plaza | 33607 | Tampa | Florida |
| Moffitt Cancer Center - McKinley Campus | 33612 | Tampa | Florida |
| Moffitt Cancer Center | 33612 | Tampa | Florida |
| Moffitt McKinley Hospital | 33612 | Tampa | Florida |
| Moffitt Cancer Center at Wesley Chapel | 33544 | Wesley Chapel | Florida |
| Memorial Hospital | 62269 | Shiloh | Illinois |
| Siteman Cancer Center - Shiloh | 62269 | Shiloh | Illinois |
| Allina Health Cancer Institute - Mercy Hospital | 55433 | Coon Rapids | Minnesota |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
